Navigation Links
New possibilities to fight pests with biological means

Corn plants emit a cocktail of scents when they are attacked by certain pests, such as a caterpillar known as the Egyptian cotton leaf worm.

Parasitic wasps use these plant scents to localize the caterpillar and deposit their eggs on it, so that their offspring can feed on the caterpillar. Soon after, the caterpillar dies and the plant is relieved from its attacker. In the case of corn, only one gene, TPS10, has to be activated to attract the parasitic wasps. This gene carries information for a terpene synthase, an enzyme forming the sesquiterpene scent compounds that are released by the plant and attract wasps toward the damaged corn plant. Since this mechanism is based only on a single gene, it might be useful for the development of crop plants with a better resistance to pests (PNAS, Early Edition, January 16-20, 2006).

At least 15 species of plants are known to release scents after insect damage, thus attracting the enemies of their enemies. Scientists term this mechanism "indirect defence". A previous cooperation by the scientists in Neuchatel and Jena showed that indirect defence functions not only above ground, but also below the earth's surface [1].

To understand the biochemistry behind this plant defence, biologists of the Max Planck institute studied corn plants, caterpillars of the species Spodoptera littoralis (Egyptian cotton leaf worm) and parasitic wasps of the species Cotesia marginiventris. Deciphering the complex mix of scents that the plants release after damage offered clues as to which classes of enzymes might be important for scent production.

The researchers isolated various genes encoding terpene synthases, the enzymes that produce these scents. One of these genes, TPS10, produced the exact bouquet of nine scent compounds that was released by the damaged corn plant. To demonstrate that TPS10 is indeed the important gene, the scientists introduced TPS10 into another plant, called Arabidopsis thaliana, which th
'"/>

Source:Max-Planck-Gesellschaft


Page: 1 2

Related biology news :

1. New possibilities for flu antiviral and vaccine research emerge from Spanish flu virus
2. Three-dimensional, miniature endoscope opens new diagnostic possibilities
3. Heart failure: Intervention possibilities from imaging programmed cell loss
4. The quest for an effective HIV vaccine presents new possibilities, challenges
5. Learning to fight an adversary that wont stay down
6. Antibiotic might fight HIV-induced neurological problems
7. NYU study reveals how brains immune system fights viral encephalitis
8. Molecular models advance the fight against malaria
9. Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries
10. Researchers find promising cancer-fighting power of synthetic cell-signaling molecule
11. Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New possibilities fight pests with biological means

(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure ... Industry Association today jointly announce the formation of ... release of its Identity and Biometric Entry ... The Framework received official support from BORDERPOL, the ... to improve and provide expertise regarding border security, ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... World Osteoporosis Day events today in Brussels. This year,s ... is a global call to take charge and improve ... is a disease that can be largely prevented through ... long run reducing healthcare budgets as well as preventing ...
... mildly lame sheep, but many do not take steps to ... and treating these animals. A study in the open access ... provide evidence for the accuracy of farmers, reporting of lameness, ... minimise footrot and other infectious foot conditions in their flocks. ...
... of Parkinson,s disease patients had insufficient levels of vitamin ... of Medicine. The fraction of Parkinson,s patients ... than patients with Alzheimer,s disease (41 percent) or healthy ... in the October issue of Archives of Neurology ...
Cached Biology News:IOF calls on European citizens to stand tall and speak out for their bones 2IOF calls on European citizens to stand tall and speak out for their bones 3Farmers can spot lame sheep, but fail to prevent footrot spread 2Lack of vitamin D linked to Parkinson's disease 2Lack of vitamin D linked to Parkinson's disease 3
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... GenomeDx Biosciences today announced that a new ... genomic test for prostate cancer, was able to predict ... radical prostatectomy without adjuvant therapy. Although rapid metastasis in ... tumor genomics to identify these men who have a ... advance. The study has been published online by ...
(Date:12/22/2014)... ITRA Global, one of the largest ... real estate, has further expanded its global reach with ... Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman of ... Global / ACORPP (Australian Corporate Property and Projects) , ... property services to a wide range of clients in ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... S*BIO Pte Ltd today announced that it has ... of Singapore Award. Dr. Stephen Rhind, Senior Vice ... behalf of the company, from Mr. S. Iswaran, ... BioSpectrum awards recognize outstanding contributions to the growth ...
... Healthcare Conference on March 10 -- 29th Annual Cowen ... March 5 Gen-Probe Incorporated (Nasdaq: GPRO ... the Barclays Capital Global Healthcare Conference in Miami on ... and at the 29th Annual Cowen and Company Healthcare ...
... Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... quarter and year ended December 31, 2008. , "During ... Products Business and were able to sustain progress on ... year for TAXUS," said Dr. William Hunter, President and ...
Cached Biology Technology:S*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award 2S*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award 3Gen-Probe to Webcast Two Upcoming Investor Presentations 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 28
Zonula Adherens Sampler Kit 10 mu g each...
Purified anti-SOCS3...
Tumor Suppressor Sampler Kit 10 mu g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Biology Products: